Trastuzumab (Herceptin) in Cancer: Mechanism, Indications, and Safety

Trastuzumab, also known by its brand name Herceptin, is a targeted monoclonal antibody used in the treatment of HER2-positive cancers. It was one of the first therapies designed to specifically target a molecular abnormality driving tumor growth. This marked a major shift from traditional chemotherapy toward precision oncology.

HER2 (human epidermal growth factor receptor 2) is overexpressed in a subset of cancers, particularly breast and gastric cancers. This overexpression leads to aggressive tumor behavior and poor prognosis if left untreated. Trastuzumab directly targets this receptor and disrupts cancer-promoting signals.

In this article, we will explore what Trastuzumab is, how it works at the molecular level, its main clinical indications, and key safety and resistance considerations. This structured overview is designed for students, researchers, and healthcare professionals interested in cancer drug mechanisms and clinical application.

I. What Is Trastuzumab?

Drug Classification and Molecular Characteristics

Trastuzumab is a humanized monoclonal antibody. It belongs to the IgG1 subclass. The drug is designed to specifically bind to the extracellular domain of the HER2 receptor. Unlike chemotherapy, Trastuzumab does not act on all rapidly dividing cells. Instead, it targets cancer cells that overexpress HER2.

At the molecular level, Trastuzumab is produced using recombinant DNA technology. Its humanized structure reduces immunogenicity and allows repeated administration with good tolerability.

HER2 as a Therapeutic Target

HER2 is a transmembrane receptor involved in cell growth and survival signaling. In normal cells, HER2 expression is tightly regulated. In some cancers, HER2 is overexpressed or amplified, leading to uncontrolled proliferation and resistance to apoptosis.

HER2 overexpression is most commonly observed in:

1. Breast cancer
2. Gastric cancer
3. Gastroesophageal junction cancer

Because HER2 drives tumor aggressiveness, it represents an ideal target for precision therapy.

Development, Brand Name, and Biosimilars

Trastuzumab was developed in the 1990s and approved after clinical trials showed significant survival benefits in HER2-positive breast cancer. It is marketed under the brand name Herceptin.

Several biosimilars are now available. These agents have comparable efficacy, safety, and quality to the original product. The availability of biosimilars has improved global access to HER2-targeted therapy and reduced treatment costs.

II. Mechanism of Action of Trastuzumab

HER2 Signaling Pathways in Cancer

HER2 is part of the epidermal growth factor receptor family. When overexpressed, it activates key oncogenic pathways. The most important are:

1. PI3K–AKT pathway, which promotes cell survival
2. MAPK pathway, which drives cell proliferation

Persistent activation of these pathways leads to rapid tumor growth, resistance to apoptosis, and increased metastatic potential.

Inhibition of Tumor Cell Proliferation

Trastuzumab binds to the extracellular domain of HER2. This binding blocks receptor activation and limits downstream signaling. As a result:

• Cell cycle progression is reduced
• Proliferation signals are weakened
• Tumor growth slows down

Trastuzumab also promotes receptor internalization and degradation, further decreasing HER2 signaling at the cell surface.

Immune-Mediated Antitumor Effects (ADCC)

In addition to direct signaling inhibition, Trastuzumab activates the immune system. Its IgG1 structure allows interaction with immune effector cells.

This leads to antibody-dependent cell-mediated cytotoxicity (ADCC):

1. Trastuzumab-coated tumor cells are recognized by natural killer cells
2. Immune cells release cytotoxic molecules
3. Cancer cells undergo cell death

This immune-mediated mechanism is a key contributor to the clinical efficacy of Trastuzumab.

III. Clinical Indications and Therapeutic Use

HER2-Positive Breast Cancer

linicians most widely use Trastuzumab to treat HER2-positive breast cancer, where they indicate it for both:

1. Early-stage disease, as adjuvant or neoadjuvant therapy
2. Metastatic disease, as first-line or subsequent treatment

The drug significantly improves disease-free survival and overall survival. Oncologists commonly combine it with chemotherapy or other HER2-targeted agents to improve treatment outcomes.therapeutic efficacy.

HER2-Positive Gastric and Gastroesophageal Cancers

Trastuzumab treats HER2-positive gastric and gastroesophageal junction cancers, where HER2 overexpression drives aggressive disease and poor prognosis.

When added to standard chemotherapy:

• Tumor response rates improve
• Trastuzumab improves survival outcomes.
• Treatment remains biomarker-driven

This highlights the importance of molecular testing beyond breast cancer.

Patient Selection and HER2 Testing

Accurate patient selection is essential for Trastuzumab therapy. Only tumors with confirmed HER2 overexpression or gene amplification benefit from treatment.

ncologists prescribe Trastuzumab as monotherapy or in combination regimens:

1. Immunohistochemistry (IHC) to assess protein expression
2. Fluorescence in situ hybridization (FISH) to detect gene amplification

Proper testing ensures effective treatment and avoids unnecessary toxicity.

Treatment Strategies and Combination Therapy

Oncologists prescribe Trastuzumab as monotherapy or in combination regimens.e used as:

• Monotherapy in selected cases
• Combination therapy with chemotherapy or other targeted drugs

Combination regimens improve outcomes by targeting multiple pathways. Treatment duration and scheduling depend on cancer type, disease stage, and patient tolerance.

IV. Safety Profile, Resistance, and Clinical Monitoring

Cardiotoxicity and Cardiac Monitoring

The most clinically significant adverse effect of Trastuzumab is cardiotoxicity. It can lead to a reduction in left ventricular ejection fraction and, in rare cases, heart failure.

Key clinical points include:

1. Higher risk when combined with anthracyclines
2. Often reversible after treatment interruption
3. Requires baseline and periodic cardiac assessment

Clinicians routinely use echocardiography or MUGA scans to monitor cardiac function during therapy.

Other Adverse Effects and Tolerability

Patients generally tolerate Trastuzumab better than conventional chemotherapy. Common adverse effects include:

• Infusion-related reactions
• Fatigue
• Nausea and headache

Most side effects are mild to moderate and occur early in treatment. Severe toxicities are uncommon with proper monitoring.

Mechanisms of Resistance

Despite its efficacy, some tumors develop primary or acquired resistance to Trastuzumab. Researchers have identified several mechanisms:

1. Alterations in the HER2 receptor
2. Activation of alternative signaling pathways
3. Loss of immune-mediated antitumor response

Resistance often necessitates treatment modification or combination with other HER2-targeted agents.

Clinical Monitoring and Risk Management

Effective use of Trastuzumab requires structured monitoring throughout treatment:

• Regular cardiac evaluations
• Assessment of treatment response
• Early detection of adverse effects

Close clinical follow-up improves safety, maximizes therapeutic benefit, and supports long-term disease control.

Conclusion

Trastuzumab has transformed the management of HER2-positive cancers by introducing a targeted, biomarker-driven approach to therapy. By directly inhibiting HER2 signaling and engaging the immune system, it delivers significant clinical benefits with a manageable safety profile.

Its success highlights the importance of molecular testing, patient selection, and clinical monitoring in modern oncology. Despite challenges such as cardiotoxicity and drug resistance, Trastuzumab remains a cornerstone of HER2-targeted treatment and a model for precision cancer therapy.

References:

1. Martín M, Pandiella A, Vargas-Castrillón E, Díaz-Rodríguez E, Iglesias-Hernangómez T, Martínez Cano C, Fernández-Cuesta I, Winkow E, Perelló MF. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. 2024 Jun;198:104355. doi: 10.1016/j.critrevonc.2024.104355.
2. Zouein J, Karam E, Strickler JH, Kourie HR. Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker. Target Oncol. 2024 Sep;19(5):705-710. doi: 10.1007/s11523-024-01079-4.
3. Indini A, Rijavec E, Grossi F. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Int J Mol Sci. 2021 Apr 30;22(9):4774. doi: 10.3390/ijms22094774.
4. von Arx C, De Placido P, Caltavituro A, Di Rienzo R, Buonaiuto R, De Laurentiis M, Arpino G, Puglisi F, Giuliano M, Del Mastro L. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev. 2023 Feb;113:102500. doi: 10.1016/j.ctrv.2022.102500.
5. Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021 Jul;188(1):21-36. doi: 10.1007/s10549-021-06280-x.